NanoViricides Inc. (NNVC)

[changes_iv]

Clinical Trials in Q4 2014 means it is as early as nine months away. If you take another look to a "worth remembering" list of events and/or PRs, by robi-1-kenobi, (11)PRs that could involve additional PRs perhaps to bring up the list of events/PRs to nearly double...all in nine months to October 2014!!! What do you think is all that exposure in the printed media, radio and tv is going to do to the pps from now to October 2014?

NanoViricides, Inc. has established, and build upon, associations with prestigious institutions/collaborators in the past, all with successful results, on the testing of nanoviricides.

Examples of those results/relationships:

WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTCBB: NNVC.OB) (the "Company") reports that post-infection treatment with its optimized FluCide™ drug candidates achieved 1,000-fold reduction in the levels of infectious virus in the lungs of animals with a lethal level of influenza virus infection. These findings corroborate the previously reported findings of both increased animal survival and protection of the lungs from influenza virus tissue damage in FluCide-treated animals in the most recent H1N1 influenza study.

Read more: Treatment with NanoViricides FluCide™ Drug Candidates Resulted in a 1000-fold Reduction of Viral Load in the Lungs of Animals - FiercePharma http://www.fiercepharma.com/press-releases/treatment-nanoviricides-flucide-drug-candidates-resulted-1000-fold-reductio#ixzz2qlrPPmcB

another example:

WEST HAVEN, Conn.--(BUSINESS WIRE)--Nov. 4, 2013-- NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"), announced today that theDengueCide evaluation contract has been renewed with Dr. Eva Harris’ Laboratory at the University of California, Berkeley, School of Public Health, Division of Infectious Diseases and Vaccinology.

“Our relationship with Dr. Harris and her colleagues is critically important to our development program for DengueCide,” said Eugene Seymour, MD, MPH, CEO of NanoViricides. Dr. Harris has an excellent mouse model of dengue virus infection and disease that the Company used previously to evaluate its anti-dengue agents. In those studies, the nanoviricides® have shown high effectiveness. In Prof. Harris’ model of dengue vascular leak, dengue virus infection of the laboratory mouse strain, AG129, is 100% fatal when the mice are untreated. In contrast, in the same study, animals treated with one of NanoViricides' anti-dengue agents achieved an unprecedented 50% survival rate.

More steps to the upside are here now, and more are coming imho, so if you were thinking of advising friends/family to invest (not trade because that is for the well trained, armed with "tools" and experienced) now is the time because later this year, it is my fervent belief it will become harder for the small investor to accumulate significantly!

I see leifsmith's post. More news are coming!!!